12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CTAP101: Phase III started

Cytochroma began the first of 2 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 30 and 60 µg oral CTAP101 once daily for 6 months...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >